BANEOTSIN® (POWDER, OINTMENT) – PERSPECTIVE FOR USE IN COMPLEX SURGICAL TREATMENT OF PURULONECROTIC DISEASES OF THE LOWER EXTREMITIES IN PATIENTS WITH DIABETIC FOOT SYNDROME

Objective – to improve the results of the topical medical treatment of wounds in patients with various forms of diabetic foot syndrome (DFS). Materials and methods. A comparative in vitro study of the antimicrobial and osmotic activity of Baneotsin® and ointments on the basis of polyethylene glycol was done. The subject of the clinical study were 18 patients with DFS. Out of these patients 8 (44.4 %) had the neuro-ischemic form and 10 (55.6 %) had the neuropathic form. According to depth and prevalence of purulonecrotic process, in 3 (16.7 %) cases there was indicated Stage II of the process according to Wagner, in 9 (50.0 %) cases – Stage III and in 6 (33.3 %) patients – Stage IV. All patients had type 2 diabetes of severe treatment, on insulin. Average age of the patients was 61.3 ± 1.4 years. The average rate of glycated hemoglobin of patients on ad- mission to hospital was 8.4 ± 1.3 %. After radical surgical treatment of purulent foci with careful removal of all necrotic tissue all patients had surgical wounds treated with 0.2 % solution of Lavasept®. 3 (16.7 %) patients with the ulcer surface without obvious signs of perifocal inflammation had bandage with Baneotsin® powder after treatment, and after 4–5 days after detecting signs of wound process during the transition to phase II the treatment was continued under the bandage with ointment Baneotsin®. In 10 (55.6 %) cases (in the results of microbiological tests were found aerobic and obligate anaerobes) the treatment of postoperative wound was done under the bandages with 5 % Dioxydine ointment for 2–3 days. 5 (27.8 %) patients (without clinical and bacteriological data of obligate anaerobes) were treated with ointment of Levomekol immediately after the operation. After 7–10 days, the patients were discharged to the outpatient treatment phase with recommendations to continue treatment with bandages with Baneotsin® powder (for 4–5 days) and then with ointment Baneotsin®. Systemic antibiotic therapy at the hospital stage of treatment lasting more than 7 days, was used only in 4 (22.2 %) cases. Results. In patients with trophic anabrosis (3 (16.7 %) persons) it was managed to heal the defects by secondary intention in the period of up to 1 month after surgical treatment. The other wounds were prepared to run the final stage of treatment – the plastic reconstruction of the foot in the period from 10–14 days to 1 month. High ablations and fatal cases in the researched group of patients were not recorded. Conclusion. Application of the algorithm of topical drug treatment of wounds with Baneotsin® powder and ointment, polyethylene glycol based ointments having different osmotic activity, depending on the severity and extent of purulent process in soft tissues, lets to avoid the prescription of long-term systemic antibiotic therapy and to accelerate the transition of purulonecrotic wounds in the phase II of wound process.

1. Балаболкин М.И., Клебанова Е.М., Креминская В.М. Лечение сахарного диабета и его осложнений: руководство для врачей. М.: Медицина, 2005. 512 с. [Balabolkin M.I., Klebanova Е.М., Kreminskaya V.М. Treatment of diabetes mellitus and its sequellae: guidance for doctors. Мoscow: Meditsina, 2005. 512 p. (In Russ.)].

2. Krishan S., Nash F., Baker N. et al. Reduction in diabetic amputations over 11 years in a defined UK population: benefits of multidisciplinary work and continuous prospective audit. Diabetes Care 2008;31(1):99–101.

3. Vamos E.P., Bottle A., Edmonds M.E. et al. Changes in incidence of lover extremity amputations in individuals with and without diabetes in England between 2004 and 2008. Diabetes Care 2010;33(12):2592–7.

4. Гурьева И.В. Профилактика, лечение, медико-социальная реабилитация и организация междисциплинарной помощи больным с синдромом диабетической стопы: Автореф. дис. … д-ра мед. наук. М., 2001. 40 с. [Guryeva I.V. Prevention, treatment, medical and social rehabilitation and the organization of multidisciplinary care for patients with diabetic foot syndrome: Author’s abstract of thesis ... Dr. Med. Sci. Мoscow, 2001. 40 p. (In Russ.)].

5. Holman N., Yung R.J., Jeffcoate W.J. Variation in the recorded incidence of amputation of the lower limb in England. Diabetologia 2012;55(7):1919–25.

6. Kerr M. Foot care in diabetes: the economic case for change. URL: www.diabetes.nhs.uk/document.php?o=3400.

7. Светухин А.М., Прокудина М.В., Павлова М.В. и др. Микрофлора гнойно-некротических поражений стопы у больных сахарным диабетом. Антибиотики и химиотерапия 1995;40(8):400–43.[Svetukhin A.M., Prokudina М.V., Pavlova М.V. et al. Microflora of purulonecrotic wounds of the foot in patients with diabetes mellitus. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy 1995;40(8):400–43. (In Russ.)].

8. Блатун Л.А., Ляпунов Н.А. Современные возможности местного медикаментозного лечения гнойных ран мягких тканей у больных сахарным диабетом. В сб.: Труды научно-практической конференции «Современные аспекты диагностики, лечения, профилактики поражений нижних конечностей у больных сахарным диабетом». М., 1996. С. 17–24. [Blatun L.А., Lyapunov N.А. Modern possibilities of topical medical treatment of purulent wounds of soft tissues in patients with diabetes. In: Materials of the research and practical conference “Modern aspects of diagnosis, treatment and prevention of diseases of the lower extremities in diabetic patients”. Мoscow, 1996. Pp. 17–24. (In Russ.)].

9. National Diabetes Audit Executive Summary 2009–10. The NHS Information Centre, 2011.

10. Блатун Л.А. Современные йодофоры – эффективные препараты для профилактики и лечения инфекционных осложнений. Хирургия. Consilium Medicum 2005;(Прил. 1):83–90. [Blatun L.А. Modern iodophores – effective drugs for the prevention and treatment of infectious sequellae. Khirurgiya. Consilium Medicum = Surgery. Consilium Medicum 2005;(Suppl 1):83–90. (In Russ.)].

11. Блатун Л.А., Терехова Р.П., Страдомский Б.В. и др. Стелланин-ПЭГ мазь 3 %: сравнительная антимикробная активность в отношении возбудителей хирургической инфекции. Антибиотики и химиотерапия 2008;53(11–12):16–8. [Blatun L.А., Terekhova R.P., Stradomskiy B.V. et al. Stellanin-PEG ointment 3 %: comparative antimicrobial activity against surgical infectious matter. Antibiotiki i khimioterapiya = Antibiotics and chemotherapy 2008;53(11–12):16–8. (In Russ.)].

12. Блатун Л.А., Пасхалова Ю.С., Чекмарева И.А. и др. Офломелид (офлоксацин-содержащая мазь на ПЭГ-основе). Клинико-лабораторная эффективность при лечении больных с инфекцией кожи и мягких тканей. Сборник материалов 1-го Международного конгресса «Раны и раневые инфекции». М., 2012. С. 45–7. [Blatun L.А., Paskhalova Yu.S., Chekmareva I.А. et al. Oflomelid (ofloxacin-containing ointment on PEG basis). Clinical and laboratory strength in the treatment of patients with infections of the skin and soft tissues. In: The collection of materials of the 1st International Congress “The wounds and wound infections”. Moscow, 2012. Pp. 45–7. (In Russ.)].

13. Блатун Л.А., Вишневский А.А., Жуков А.О. и др. Пронтосан в комплексном лечении хронических ран. Сборник материалов 1-го Международного конгресса «Раны и раневые инфекции». М., 2012. С. 44–5. [Blatun L.А., Vishnevskiy A.A., Zhukov А.О. et al. Prontosan in complex treatment of inveterate wounds. In: The collection of materials of the 1st International Congress “The wounds and wound infections”. Moscow, 2012. Pp. 44–5. (In Russ.)].

14. Крастин О.А., Светухин А.М., Блатун Л.А. и др. Эффективность препарата Стизамет при лечении ран мягких тканей. Ретиноиды. Альманах. Вып. 28. Мазь Стизамет. М.: ЗАО «Ретиноиды», 2009. С. 71–6. [Krastin О.А., Svetukhin А.М., Blatun L.А. et al. Strength of Stizamet in soft tissue wounds treatment. In: Retinoids. Almanac. Vol. 28. Ointment Stizamet. Moscow: JSC “Retinoids”, 2009. Pp. 71–6. (In Russ.)].

15. Попов Д.А., Анучина Н.М., Терентьев А.А. и др. Диоксидин: антимикробная активность и перспективы клинического применения на современном этапе. Антибиотики и химиотерапия 2013;58(3–4):38–43. [Popov D.А., Anuchina N.М., Terent’yev А.А. et al. Dioxydin: antimicrobial activity and perspectives of clinical usage on the modern stage. Antibiotiki i khimioterapiya = Antibiotics and chemotherapy 2013;58(3–4):38–43. (In Russ.)].

16. Митиш В.А., Пасхалова Ю.С., Ерошкин И.А. и др. Гнойно-некротические поражения при нейроишемической форме синдрома диабетической стопы. Хирургия 2014;(1):48–53. [Mitish V.А., Paskhalova Yu.S. , Eroshkin I.А. et al. Purulonecrotic diseases in neuro-ischemic form of diabetic foot syndrome. Khirurgiya = Surgery 2014;(1):48–53. (In Russ.)].

17. Буслаев О.А., Ильин И.А., Астапенко И.В. Опыт применения препарата Банеоцин в лечении инфицированных ран, ожогов и трофических язв. Бюллетень Восточно-Сибирского научного центра СО РАМН 2006;(4):44–6. [Buslaev О.А., Il’yin I.А., Astapenko I.V. Experience of Baneotsin usage in the treatment of infected wounds, burns and trophic ulcers. Bulleten’ Vostochno-Sibirskogo otdeleniya SO RAMN = Bulletin of the East Siberian Scientific Center of the SB RAMS 2006;(4):44–6. (In Russ.)].

18. Белькова Ю.А., Козлов Р.С., Кречикова О.И. и др. Эффективность и безопасность местного использования комбинации бацитрацина и неомицина в сравнении с хлорамфениколом в терапии неосложненных хирургических инфекций кожи и мягких тканей у взрослых амбулаторных пациентов. Клиническая микробиология и антимикробная химиотерапия 2013;15(2):131–42. [Bel’kova Yu.А., Kozlov R.S., Krechikova О.I. et al. Strength and safety of topical use combination of bacitracin and neomycin compared to chloramphenicol in uncomplicated surgical treatment of skin and soft tissues in adult outpatients. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy 2013;15(2):131–42. (In Russ.)].

19. Блатун Л.А., Жуков А.О., Амирасланов Ю.А. и др. Клинико-лабораторное изучение разных лекарственных форм банеоцина при лечении раневой инфекции. Хирургия 2009;(9):63–9. [Blatun L.А., Zhukov А.О., Amiraslanov Yu.А. et al. Clinical and laboratory study of different dosage of baneotsin in the treatment of wound infections. Khirurgiya = Surgery 2009;(9):63–9. (In Russ.)].